BBIO Stock Recent News

BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday.

Bayer snagged commercial rights to BridgeBio's lead asset, acoramidis, in Europe for $310 million. BridgeBio stock is nearing a breakout.

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $0.95. This compares to loss of $0.87 per share a year ago.

BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotechnology companies are intriguing investment vehicles because they are part of a pretty speculative industry that allows investors to grow their investments rapidly — if they pick a company before it releases positive results. But on the flip side, a single negative press release could send a stock tumbling with biotech stocks being so volatile.

BridgeBio Pharma, Inc. expects results from the phase 1/2 study, using gene therapy BBP-631 for the treatment of patients with congenital adrenal hyperplasia, in early 2024. The congenital adrenal hyperplasia treatment market is expected to reach $892 million by 2033. Potential FDA acceptance of regulatory application of acromidis for the treatment of patients with ATTR-CM, expected within 60 days after submission achieved December 5th of 2023.

BridgeBio's FDA filing for acoramidis and advances in KRAS mutation cancer treatment contrast with growing financial losses. Acoramidis competes with Pfizer's ATTR-CM treatments; BBIO's oncology focus includes promising KRAS inhibitors and RAS-targeting strategies. Financially, the Company reports increased net loss and share count, yet possesses a solid short-term solvency with high long-term debts.

With several big pharmas set to lose patent protection for key drugs this decade, the merger and acquisition scene is widely expected to heat up in 2024. These two biotechs have repeatedly been rumored to be receiving takeover interest from larger peers.

For most of the year, the Russell 2000 has lagged far behind its peers, the S&P500 and the Nasdaq. However, the small-to-mid cap index appears to be closing the gap.

PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM will be presented at the AHA Scientific Sessions 2023, taking place in Philadelphia, Pennsylvania on November 11 - 13, 2023. As previously announced, a highly statistically significant result was observed on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p